



The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

615.ACUTE MYELOID LEUKEMIAS: COMMERCIALLY AVAILABLE THERAPIES, EXCLUDING TRANSPLANTATION AND CELLULAR IMMUNOTHERAPIES

Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell

Transplantation: Evidence from a Large Real-World Italian Study

Fabio Guolo, MDPhD^{1,2}, Luana Fianchi, MDPhD³, Maria Paola Martelli, MDPhD⁴, Patrizia Chiusolo³, Federico Lussana, MD⁵, Francesco Grimaldi, MD⁶, Federica Pilo, MD⁷, Michela Rondoni⁸, Carla Fili, MD⁹, Debora Capelli, MD¹⁰, Massimo Breccia¹¹, Sara Mastaglio, MD¹², Monica Bocchia, MD¹³, Monica Fumagalli, MD¹⁴, Sara Galimberti, MD PhD¹⁵, Valentina Mancini, MD¹⁶, Anna Lina Piccioni, MD¹⁷, Luca Maurillo, MD¹⁸, Raffaele Palmieri, MD¹⁸, Andrea Corbingi, MD¹⁹, Calogero Vetro, MD²⁰, Alessandra Sperotto, MD²¹, Federica Gigli, MD²², Patrizia Zappasodi, MD²³, Antonio Mulé, MD²⁴, Erika Borlenghi, MD²⁵, Michelina Dargenio, MD²⁶, Federica Lessi, MD²⁷, Marco Cerrano, MD²⁸, Alessandro Isidori, MDPhD²⁹, Lorenzo Brunetti, MD³⁰, Cristina Papayannidis, MD³¹, Monia Lunghi, MD PhD³², Caterina Alati, MD³³, Samuele Gatani³⁴, Francesco Mannelli, MD³⁵, Nicola Fracchiolla, MD³⁶, Michele Gottardi, MD²¹, Roberto Cairoli, MD³⁷, Felicetto Ferrara, MD³⁸, Roberto Massimo Lemoli, MD^{39,40}, Adriano Venditti, MD⁴¹, Livio Pagano, MD³, Elisabetta Todisco, MD³⁴

¹ IRCCS Ospedale Policlinico San Martino, Genoa, Italy

² Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy

³ Dipartimento di Scienze Radiologiche Radioterapiche ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy

⁴ Dipartimento di Medicina e Chirurgia, Hematology, Department of Medicine and Surgery, University of Perugia and "Santa Maria della Misericordia" Hospital, Perugia, ITA

⁵ Department of Oncology-Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

⁶ Department of Clinical Medicine and Surgery, Hematology Unit, University of Naples Federico II, Naples, ITA

⁷ SC di Ematologia e CTMO, Ospedale Oncologico di Riferimento Regionale "A. Businco", ARNAS "G. Brotzu", Cagliari, Italy

⁸ Hematology Unit & Metropolitan Transplant Network, AUSL Romagna, Ravenna, Italy

⁹ Division of Hematology and Stem Cell Transplantation, University Hospital ASUF, Udine, Italy

¹⁰ Clinica di Ematologia, Azienda Ospedaliero-Universitaria delle Marche, Ospedali Riuniti di Ancona, Ancona, ITA

¹¹ Department of Translational and Precision Medicine, Hematology-Sapienza University, Rome, Italy

¹² Hematology and Bone Marrow Transplant, Unit San Raffaele Scientific Institute, Milan, Italy

¹³ UOC Ematologia, Azienda ospedaliero-universitaria Senese, Siena, Italy

¹⁴ Hematology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy

¹⁵ Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy

¹⁶ Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

¹⁷ Dipartimento di Ematologia, Azienda Ospedaliera San Giovanni Addolorata, Rome, Italy

¹⁸ Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy

¹⁹ Hematology, Polo Universitario Pontino, "Sapienza", S.M. Goretti Hospital, Latina, Italy

²⁰ Division of hematology, A.O.U. Policlinico G.Rodolico - S. Marco, Catania, Italy

²¹ Onco Hematology, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Castelfranco Veneto, Italy

²² Divisione di Oncoematologia, European Institute of Oncology, Milan, Italy

²³ Clinica Ematologica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

²⁴ Division of Hematology 1, Azienda Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy

²⁵ Hematology, ASST Spedali Civili, Brescia, Italy

²⁶ Divisione di Ematologia e Centro Trapianti, CSE Vito Lazzi, Lecce, Italy

²⁷ Divisione di Ematologia e Centro Trapianti, Azienda Ospedaliera Universitaria di Padova, Padova, Italy

²⁸ Division of Hematology, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy

²⁹ Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy

³⁰ Clinica di Ematologia, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy

³¹ Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

³² Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

³³ U.O.C. Ematologia, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

³⁴ Hematology Department, ASST Valle Olona, Varese, Italy

³⁵ CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

³⁶ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy

³⁷ Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

³⁸ Divisione di Ematologia, Ospedale Cardarelli, Napoli, Italy

³⁹ Clinic of Hematology, Department of Internal medicine (DiMI), University of Genoa, Genoa, Italy

⁴⁰ Clinica Ematologica, Dipartimento di Oncologia e Ematologia, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

⁴¹ Department of Onco-Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy

Background: CPX-351, has been approved for the treatment of patients diagnosed with Acute Myeloid Leukemia (AML) arising from a previous myelodysplastic syndrome (s-AML) or secondary to chemotherapy (t-AML) as per former WHO 2016 classification, following results from the phase III trial (Lancet et al, JCO2018). Long term results from the trial confirmed that the benefit from CPX-351 over conventional 3+7 induction was maintained both in patients proceeding or not to allogeneic stem cell transplantation consolidation (HSCT). However, the information on the optimal duration of treatment with CPX-351 or the best timing for HSCT consolidation are still incomplete. Furthermore, there is also scarce data on the efficacy of CPX-351 among *NPM1* or *FLT3-ITD* mutated AML or in patient with low risk AML according to European Leukemia Net (ELN) classification, as those subgroups are rare among t-AML and s-AML.

Aims: The aim of this study is to analyze the outcome of CPX-351 treatment in a large cohort of patient who received commercially available treatment in Italy since the approval of the drug, in order to identify the optimal duration of treatment, the best timing for HSCT and to evaluate the efficacy among more rare secondary AML subtypes.

Methods: 513 elderly (median age 65.6 years, range 19-79) s-AML or t-AML patients who received CPX-351 treatment in 38 Italian Centers since January 2019 were retrospectively included in this study. All patients received CPX-351 as per Italian Drug Authority (AIFA) approval, allowing up to two induction cycles and up to two consolidation. Diagnostic workup was performed as per internal standard in all patients. Eligible patients proceeded to HSCT consolidation as per internal standard of each Center. 108 (21.1%) and 405 (78.9%) patients were diagnosed with t-AML or s-AML, respectively. *NPM1* mutation were found in 31 patients (6%), *FLT3-ITD* mutation was present in 24 patients (4.6%). ELN 2017 score was favorable, intermediate or high in 27 (5.2%), 177 (34.5%) and 309 (60.3%) patients, respectively. Most patients had relevant comorbidities (84%), mainly cardiovascular disease (43%), type II diabetes (39%).

After induction 1, 297/513 patients (58%) achieved a complete remission (CR). 72 patients failing to achieve CR received induction 2. After induction 2, CR was achieved in 340/513 patients (66.3%). CR rate was significantly higher among *NPM1* mutated patients ($p < 0.05$) and among ELN 2017 favorable risk patients if compared to intermediate or high risk ($p < 0.05$), whereas was not affected by *FLT3-ITD* mutations. Among responding patients, 118 (34.7%), 137 (40.3%) and 85 (25%) received none, one or two consolidation cycles, respectively. HSCT consolidation in first CR was performed in 166/340 responding patients (48.8%). 30 and 60-days mortality were 5.2 and 8.2%, respectively.

After a median follow-up of 23.66 months (CI 95% 23.11 - 26.01), median OS was 16.23 months (CI 95% 13.6 - 18.9).

OS was significantly influenced by *NPM1* mutational status ($p < 0.05$) and ELN 2017 risk score ($p < 0.05$, Fig. 1A). Of note, *NPM1* mutated patients and ELN 2017 low-risk patients showed a very good outcome (Median OS 24.6 months for *NPM1* mutated patients and not reached in ELN 2017 favorable risk patients).

In a landmark analysis including patients alive and in CR at day 90, HSCT was the strongest predictor of longer survival (Median OS not reached and 16.3 months for patients receiving or not HSCT, respectively, $p < 0.05$). In the same landmark model, completion of all allowed CPX-351 treatment was beneficial only in patients not proceeding to HSCT (median OS 20.36 and 12.2 months in patients receiving 2 or less CPX-351 consolidation without HSCT, respectively, $p < 0.05$, Fig. 1B), whereas in patients receiving HSCT consolidation further CPX-351 treatment after cycle 1 did not improve results (Median OS not reached, 35 and 28.4 months in HSCT patients receiving 0, 1 or 2 CPX-351 consolidations, respectively, $p = n.s.$)

Conclusions: Our large cohort confirms the efficacy of CPX-351 treatment and suggests that CPX-351 may be beneficial also in *NPM1* mutated and ELN 2017 favorable risk patients. In eligible patients, HSCT should probably be performed as soon as a CR is achieved, whereas patients not proceeding to HSCT may still have a long survival if two consolidations are administered. In a future perspective, maintenance strategies may further improve the results.

Disclosures Martelli: Abbvie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Laboratoires Delbert: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Jazz Pharmaceuticals: Consultancy, Honoraria. **Lus-sana:** Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Speakers Bureau; Clinigen: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees; Amgen: Speakers Bureau. **Brescia:** Incyte: Honoraria; AbbVie: Honoraria; Novartis: Honoraria; AOP: Honoraria; Pfizer: Honoraria; BMS: Honoraria. **Bocchia:** Novartis: Honoraria; Incyte: Honoraria; BMS: Honoraria. **Galimberti:**

Abbvie, Janssen, Novartis, Roche, Jazz, Astra Zeneca, Pfizer, Incyte: Speakers Bureau. **Palmieri:** Pfizer: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Jazz: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria. **Vetro:** Jazz Pharmaceuticals: Honoraria; BMS: Honoraria; ABBVIE: Honoraria. **Zappasodi:** Amgen, Pfizer, Abbvie, Astellas: Honoraria. **Borlenghi:** AbbVie, BMS: Consultancy; Amgen, Incyte: Other: travel grants. **Cerrano:** Insight Novartis Servier Abbvie Janssen Jazz Astellas Italfarmaco: Honoraria. **Papayannidis:** Abbvie, Astellas, Servier, Menarini/Stemline, BMS, Pfizer, Amgen, Janssen, Incyte, Novartis: Honoraria; Pfizer, Astellas, Janssen, GSK, Blueprint, Jazz Pharmaceuticals, Abbvie, Novartis, Delbert Laboratoires: Membership on an entity's Board of Directors or advisory committees. **Alati:** AbbVie: Honoraria; Jazz: Honoraria. **Fracchiolla:** Abbvie, Jazz, Pfizer, Amgen: Other: travel grants; Abbvie, Jazz, Pfizer, Amgen: Speakers Bureau. **Ferrara:** ABBVIE: Honoraria. **Venditti:** Medac: Consultancy; Janssen: Consultancy, Honoraria, Other: travel support ; AbbVie: Consultancy, Honoraria, Other: travel support ; Jazz: Consultancy, Honoraria, Other: travel support ; Amgen: Consultancy, Honoraria, Other: travel support ; Pfizer: Consultancy, Honoraria, Other: travel support , Speakers Bureau; Novartis: Consultancy, Honoraria, Other: travel support . **Pagano:** Janssen: Honoraria; Pfizer: Honoraria; Gilead: Honoraria; Jazz: Honoraria; Novartis: Honoraria; Menarini: Honoraria; Moderna: Honoraria; AstraZeneca: Honoraria.

<https://doi.org/10.1182/blood-2023-189025>

Figure 1:

- A) Overall Survival in All Patients according to ELN 2017 risk score
B) Overall Survival according to number of consolidations in non HSCT patients (landmark analysis)




Figure 1